Select your Market

Second Quarter: Group Remains on Course in a Challenging Environment

The company registered the effects of the Covid-19 pandemic in all business sectors in the second quarter. Group sales increased by 3.7% to € 4.1 billion. EBITDA pre fell by -5.7% to € 1.1 billion.

Overview and outlook

Overview of Q2 2020

  • Sales rise by 3.7% to € 4.1 billion, EBITDA pre declines by -5.7% to € 1.1 billion
  • Healthcare and Performanca Materials more strongly affected by the Covid-19 pandemic than Life Science
  • Process Solutions drives growth of Life Science

Outlook for fiscal 2020

  • Assumptions regarding the further course of the pandemic largely unchanged
  • Group sales between € 16.9 billion and € 17.7 billion expected; lower end of range raised for expected EBITDA pre; forecast is now € 4.45 billion to € 4.85 billion 
852 852 Pull Quote Oschmann Stefan 2018 Small

Despite considerable pandemic-related obstacles in some businesses, overall we did well in the second quarter. In recent months, we again proved the strengths of our diversified business model with three strong, innovation-driven business sectors.

Stefan Oschmann

Chairman of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany

Annual Reports Archive

Find previous Annual Reports, Corporate Governance Reports & Statements in our archive.
Read more

Related News

View All News
  1. Press Releases

    Second Quarter: Group Remains on Course in a Challenging Environment

    Merck KGaA, Darmstadt, Germany, registered the effects of the Covid-19 pandemic in all business sectors in the second quarter. Healthcare and Performance Materials were affected most strongly.

    2020/08/06

Andreas Cezanne

Financial Communications

Constantin Fest

Head of Investor Relations

+49 6151 72-5271

+49 6151 72 91-5271